Abstract
In the 2023-2024 season, systematic immunization with the monoclonal antibody nirsevimab was recommended in Spain. The impact that this immunization program had on the target population of the program is analyzed. Pre-post ecological study comparing 2023-24 vs 2022-23 season. The variation in incidence is described by age groups (0-5, 6-11 and 12-59 months) and hospitalization. Incidence rates were calculated and relative risks (RR) were estimated for each group. The results were very heterogeneous depending on the age group. In children 0-5 months old the RR was 0.16 (0.10-0.25); in those aged 6-11 months, RR of 0.90 (0.56-1.42); and in those aged 12-59 months, RR 1.36 (1.06-1.74). The greatest decrease in risk was in hospitalized children under 6 months, RR 0.13 (0.07-0.22). The results support the positive impact that this campaign had, especially on hospitalizations.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call